Table 3 Multivariable analysis of factors influencing overall and disease-specific survival in test set (n=95)

From: High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome

Variable

HR

95% CI

P-value

Overall survival

 Age (per year increase)

1.002

0.984–1.020

0.81

 AML (vs MDS/CMML)

1.878

1.079–3.266

0.03

 High-risk karyotypea

1.874

0.968–3.627

0.06

 Treatment with stem cell transplant

0.210

0.106–0.418

<0.0001

 p53 immunohistochemistry positivity (≥1% 3+ cells)

3.434

1.751–6.735

<0.0001

Disease-specific survival

 Age (per year increase)

0.982

0.982–1.019

0.97

 AML (vs MDS/CMML)

2.440

1.373–4.338

0.002

 High-risk karyotypea

2.395

1.196–4.795

0.014

 Treatment with stem cell transplant

0.197

0.097–0.401

<0.0001

 p53 immunohistochemistry positivity (≥1% 3+ cells)

3.882

1.931–7.806

<0.0001

  1. AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic syndrome.
  2. aDefined as Revised International Prognostic Scoring System high or very high risk for MDS/CMML cases and United Kingdom Medical Research Council adverse risk for AML cases.
Back to article page